

Renata R Urban

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1900865/publications.pdf>

Version: 2024-02-01

36
papers

558
citations

623699

14
h-index

677123

22
g-index

36
all docs

36
docs citations

36
times ranked

1088
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States. <i>Gynecologic Oncology</i> , 2015, 136, 491-497.	1.4	58
2	Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations. <i>Gynecologic Oncology</i> , 2021, 160, 817-826.	1.4	51
3	Ovarian cancer outcomes: Predictors of early death. <i>Gynecologic Oncology</i> , 2016, 140, 474-480.	1.4	47
4	Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass. <i>Gynecologic Oncology</i> , 2017, 147, 291-295.	1.4	35
5	The Cost of Initial Care for Medicare Patients With Advanced Ovarian Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 429-437.	4.9	34
6	Comprehensive care in gynecologic oncology: The importance of palliative care. <i>Gynecologic Oncology</i> , 2015, 137, 193-202.	1.4	33
7	Robotic, Laparoscopic, or Open Hysterectomy: Surgical Outcomes by Approach in Endometrial Cancer. <i>Journal of Minimally Invasive Gynecology</i> , 2018, 25, 986-993.	0.6	28
8	Use of Statin Medications Following Diagnosis in Relation to Survival among Women with Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1127-1133.	2.5	23
9	Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II. <i>Gynecologic Oncology</i> , 2021, 160, 827-834.	1.4	20
10	Physicians' Perspectives and Practice Patterns Toward Opportunistic Salpingectomy in High- and Low-Risk Women. <i>Cancer Investigation</i> , 2017, 35, 51-61.	1.3	19
11	Route of hysterectomy and surgical outcomes from a statewide gynecologic oncology population: is there a role for vaginal hysterectomy?. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 348.e1-348.e9.	1.3	15
12	Racial disparities in the utilization of preventive health services among older women with early-stage endometrial cancer enrolled in Medicare. <i>Cancer Medicine</i> , 2017, 6, 2153-2163.	2.8	15
13	The end of life costs for Medicare patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 148, 336-341.	1.4	15
14	Fellow Perceptions of Residency Training in Obstetrics and Gynecology. <i>Journal of Surgical Education</i> , 2019, 76, 93-98.	2.5	14
15	Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations. <i>Gynecologic Oncology Reports</i> , 2019, 29, 113-117.	0.6	13
16	The association between HIV infection and cervical cancer presentation and survival in Uganda. <i>Gynecologic Oncology Reports</i> , 2020, 31, 100516.	0.6	13
17	Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e47.	2.2	10
18	Preoperative hyponatremia in women with ovarian cancer: An additional cause for concern?. <i>Gynecologic Oncology</i> , 2016, 142, 471-476.	1.4	10

#	ARTICLE	IF	CITATIONS
19	Opioid use in gynecologic oncology in the age of the opioid epidemic: Part I - Effective opioid use across clinical settings, a society of gynecologic oncology evidence-based review. <i>Gynecologic Oncology</i> , 2018, 149, 394-400.	1.4	10
20	Postoperative narcotic use in patients with ovarian cancer on an Enhanced Recovery After Surgery (ERAS) pathway. <i>Gynecologic Oncology</i> , 2020, 156, 624-628.	1.4	10
21	Combined symptom index and second-generation multivariate biomarker test for prediction of ovarian cancer in patients with an adnexal mass. <i>Gynecologic Oncology</i> , 2018, 150, 318-323.	1.4	9
22	Post-diagnosis use of antihypertensive medications and the risk of death from ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 154, 426-431.	1.4	9
23	Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates. , 2021, 9, e003122.		9
24	Metastases from lung adenocarcinoma within a leiomyoma: A case report. <i>Gynecologic Oncology Reports</i> , 2017, 20, 27-29.	0.6	8
25	Obstetrician-gynecologists' knowledge and opinions about the United States Preventive Services Task Force (USPSTF) committee, the Women's Health Amendment, and the Affordable Care Act: National study after the release of the USPSTF 2009 Breast Cancer Screening Recommendation Statement. <i>Preventive Medicine</i> , 2014, 59, 79-82.	3.4	7
26	Opioid use in gynecologic oncology in the age of the opioid epidemic: Part II - Balancing safety & accessibility. <i>Gynecologic Oncology</i> , 2018, 149, 401-409.	1.4	7
27	Routine proteinuria monitoring for bevacizumab in patients with gynecologic malignancies. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 771-776.	0.9	5
28	Evaluation of a Validated Biomarker Test in Combination With a Symptom Index to Predict Ovarian Malignancy. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 233-238.	2.5	5
29	Pilot study of a condensed communication skills workshop for gynecologic oncology fellows. <i>Gynecologic Oncology Reports</i> , 2019, 30, 100492.	0.6	4
30	Two cases of extragonadal malignant transformation of endometriosis after TAH/BSO for benign indications. <i>Gynecologic Oncology Reports</i> , 2019, 28, 23-25.	0.6	4
31	Society of Gynecologic Oncology recommendations for fellowship education during the COVID-19 pandemic and beyond: Innovating programs to optimize trainee success. <i>Gynecologic Oncology</i> , 2021, 160, 271-278.	1.4	4
32	Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2016, 143, 389-392.	1.4	3
33	Fellow perceptions of residency training in obstetrics and gynecology. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 218, 461-462.	1.3	3
34	The perceptions of gynecologic oncology fellows on readiness for subspecialty training following OB/GYNRESIDENCY. <i>Gynecologic Oncology Reports</i> , 2019, 28, 104-108.	0.6	3
35	Intraperitoneal ports placed at the time of bowel resection for treatment of ovarian cancer: Complications and surgical outcomes. <i>Gynecologic Oncology</i> , 2019, 155, 220-223.	1.4	3
36	The optimal management of brain metastases from gestational trophoblastic neoplasia. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 307-315.	2.4	2